|
|
|
|
|
|
|
12.01.26 - 14:03
|
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds (GlobeNewswire EN)
|
|
|
DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 (Registration Nos. 333-262407 and 333-267637) and Form S-3 (Registration Nos. 333-252659 and 333-271082). The gross proceeds to the company from the exercise of the preferred investment options are expected to be approximately $2.1 million, prior to deducting placement agent fees and offering expenses....
|
|
|
|
|
|
|
26.12.25 - 14:03
|
Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources (GlobeNewswire EN)
|
|
|
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.03.25 - 21:09
|
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights (Business Wire)
|
|
|
-- Year-over-year revenues grew 56% in Q4 and 13% for full year --
-- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year --
-- Company plans business combination with Roosevelt Resources, Inc. --
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024.
“We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets,” said T.J. Schaefer, president and CEO. “Our focus on Zola® coconut water led to 80 percent revenue growth for the brand in the back half of the year and drove total Arcadia revenue growth above 30 percent. At the same time revenue growth was accelerating, we maintained tight cost controls, resulting in the lowest use of cash from operations since Arcadia went public a decade ago.
“In the fo...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
